KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Edwards Lifesciences (EW) EBITDA (2016 - 2025)

Historic EBITDA for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to $307.1 million.

  • Edwards Lifesciences' EBITDA fell 1240.73% to $307.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 90.59%. This contributed to the annual value of $1.4 billion for FY2024, which is 533.27% up from last year.
  • Per Edwards Lifesciences' latest filing, its EBITDA stood at $307.1 million for Q3 2025, which was down 1240.73% from $411.2 million recorded in Q2 2025.
  • Edwards Lifesciences' EBITDA's 5-year high stood at $542.1 million during Q2 2021, with a 5-year trough of $197.7 million in Q4 2022.
  • For the 5-year period, Edwards Lifesciences' EBITDA averaged around $370.8 million, with its median value being $374.4 million (2021).
  • As far as peak fluctuations go, Edwards Lifesciences' EBITDA surged by 41944.61% in 2021, and later crashed by 4719.55% in 2022.
  • Edwards Lifesciences' EBITDA (Quarter) stood at $374.4 million in 2021, then tumbled by 47.2% to $197.7 million in 2022, then skyrocketed by 75.42% to $346.8 million in 2023, then decreased by 9.86% to $312.6 million in 2024, then dropped by 1.76% to $307.1 million in 2025.
  • Its EBITDA stands at $307.1 million for Q3 2025, versus $411.2 million for Q2 2025 and $394.8 million for Q1 2025.